Abstract
An efficient computational method for hit and lead identification is described. The method that incorporate ligand information from physicogenetically related 7TM receptors, i.e. receptors with similar physicochemical features in the ligand binding pockets, have been developed to aid the construction of pharmacophore queries for mining of vendor and in-house databases to produce small focused libraries for a specific GPCR target. The physicogenetically related targets could be complementary to phylogenetically derived receptors and convey more relevance for the structure-based design approaches suitable for GPCR targets associated with no or limited ligand information. The approach is useful not only in identification of hits but also in the hit-to-lead process as constructed homology receptor models, SAR information and pharmacophore features are collectively utilized in the design of proprietary new lead series. This site-directed drug discovery approach of making smaller receptor-specific libraries displays important advantages over conventional HTSbased generation of hits. The methodology has been exemplified with the CRTH2 receptor, which was associated with minimal ligand information, to produce a small diverse library containing several useful hit series which were further converted into drugable lead series. The use of ligand and QSAR information in scaffold hopping was exemplified with MCH1R antagonists, which had been obtained via chemogenomics-enriched design. Finally, an example on how ligand relationships can be used in identifying receptor relationships was given with CCR2 antagonists to highlight the 3D relationships of GPCR targets not directly evident from either phylogenetic or physicogenetic relationships.
Keywords: 7TM receptor, beta2 receptor, CRTH2 receptor, MCH1 receptor, binding pocket, physicogenetics, chemogenomics, virtual screening, scaffold, MCH1R antagonists, GPCR targets, G Protein-Coupled Receptors, X-ray crystallography, highhroughput screening (HTS), fragment-based drug design (FBDD)
Current Topics in Medicinal Chemistry
Title: Drug Design of GPCR Ligands Using Physicogenetics and Chemogenomics - Principles and Case Studies
Volume: 11 Issue: 15
Author(s): Thomas M. Frimurer and Thomas Hogberg
Affiliation:
Keywords: 7TM receptor, beta2 receptor, CRTH2 receptor, MCH1 receptor, binding pocket, physicogenetics, chemogenomics, virtual screening, scaffold, MCH1R antagonists, GPCR targets, G Protein-Coupled Receptors, X-ray crystallography, highhroughput screening (HTS), fragment-based drug design (FBDD)
Abstract: An efficient computational method for hit and lead identification is described. The method that incorporate ligand information from physicogenetically related 7TM receptors, i.e. receptors with similar physicochemical features in the ligand binding pockets, have been developed to aid the construction of pharmacophore queries for mining of vendor and in-house databases to produce small focused libraries for a specific GPCR target. The physicogenetically related targets could be complementary to phylogenetically derived receptors and convey more relevance for the structure-based design approaches suitable for GPCR targets associated with no or limited ligand information. The approach is useful not only in identification of hits but also in the hit-to-lead process as constructed homology receptor models, SAR information and pharmacophore features are collectively utilized in the design of proprietary new lead series. This site-directed drug discovery approach of making smaller receptor-specific libraries displays important advantages over conventional HTSbased generation of hits. The methodology has been exemplified with the CRTH2 receptor, which was associated with minimal ligand information, to produce a small diverse library containing several useful hit series which were further converted into drugable lead series. The use of ligand and QSAR information in scaffold hopping was exemplified with MCH1R antagonists, which had been obtained via chemogenomics-enriched design. Finally, an example on how ligand relationships can be used in identifying receptor relationships was given with CCR2 antagonists to highlight the 3D relationships of GPCR targets not directly evident from either phylogenetic or physicogenetic relationships.
Export Options
About this article
Cite this article as:
M. Frimurer Thomas and Hogberg Thomas, Drug Design of GPCR Ligands Using Physicogenetics and Chemogenomics - Principles and Case Studies, Current Topics in Medicinal Chemistry 2011; 11 (15) . https://dx.doi.org/10.2174/156802611796391258
DOI https://dx.doi.org/10.2174/156802611796391258 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Oral HPV Infection: Current Strategies for Prevention and Therapy
Current Pharmaceutical Design Endogenous Regulators of Adult CNS Neurogenesis
Current Pharmaceutical Design Preclinical and Clinical Studies on Bryostatins, A Class of Marine-Derived Protein Kinase C Modulators: A Mini-Review
Current Topics in Medicinal Chemistry Cardiovascular-Active Venom Toxins: An Overview
Current Medicinal Chemistry Real Time Analysis of Neurotransmitters in the Brain Using a Micro-Electrode System
Current Neurovascular Research Zinc as an Appetite Stimulator - The Possible Role of Zinc in the Progression of Diseases Such as Cachexia and Sarcopenia
Recent Patents on Food, Nutrition & Agriculture Methodologic Issues in the Validation of Putative Biomarkers and Surrogate Endpoints in Treatment Evaluation for Systemic Lupus Erythematosus
Endocrine, Metabolic & Immune Disorders - Drug Targets Inhibiting Protein-Protein Interactions as an Emerging Paradigm for Drug Discovery
Mini-Reviews in Medicinal Chemistry Potential Control of Multiple Sclerosis by Cannabis and the Endocannabinoid System
CNS & Neurological Disorders - Drug Targets Patent Selections:
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Transition Metal Based Anticancer Drugs
Current Topics in Medicinal Chemistry Iatrogenic QT Abnormalities and Fatal Arrhythmias: Mechanisms and Clinical Significance
Current Cardiology Reviews In the Rush for Green Gold: Can Green Tea Delay Age-Progressive Brain Neurodegeneration?
Recent Patents on CNS Drug Discovery (Discontinued) Recurrent Pregnancy Losses
Current Women`s Health Reviews Depressed Serum 25-Hydroxyvitamin D Levels Increase Hospital Stay and Alter Glucose Homeostasis in First-ever Ischemic Stroke
Current Neurovascular Research Neuromyelitis Optica (NMO IgG+) and Genetic Susceptibility, Potential Ethnic Influences
Central Nervous System Agents in Medicinal Chemistry The Use of Human Albumin for the Treatment of Ascites in Patients with Liver Cirrhosis: Item of Safety, Facts, Controversies and Perspectives
Current Drug Safety Chemical Biology of mGlu4 Receptor Activation: Dogmas, Challenges, Strategies and Opportunities
Current Topics in Medicinal Chemistry Comparison of Glucocorticoid Receptor- and Epigenetically Regulated Genes in Proliferating Versus Growth-Arrested Neuro-2a Cells
CNS & Neurological Disorders - Drug Targets Drug Delivery Technologies and Stem Cells for Tissue Repair and Regeneration
Current Pharmaceutical Biotechnology